DK1827461T3 - Cladribin-regimen til behandling af multipel sklerose - Google Patents

Cladribin-regimen til behandling af multipel sklerose

Info

Publication number
DK1827461T3
DK1827461T3 DK05823474.1T DK05823474T DK1827461T3 DK 1827461 T3 DK1827461 T3 DK 1827461T3 DK 05823474 T DK05823474 T DK 05823474T DK 1827461 T3 DK1827461 T3 DK 1827461T3
Authority
DK
Denmark
Prior art keywords
multiple sclerosis
treatment
cladribin
regulation
preparation
Prior art date
Application number
DK05823474.1T
Other languages
English (en)
Inventor
Luca Giampiero De
Arnaud Ythier
Alain Munafo
Maria Lopez-Bresnahan
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34930135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1827461(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Priority claimed from PCT/EP2005/056954 external-priority patent/WO2006067141A1/en
Application granted granted Critical
Publication of DK1827461T3 publication Critical patent/DK1827461T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
DK05823474.1T 2004-12-22 2005-12-20 Cladribin-regimen til behandling af multipel sklerose DK1827461T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
PCT/EP2005/056954 WO2006067141A1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
DK1827461T3 true DK1827461T3 (da) 2012-03-26

Family

ID=34930135

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05823474.1T DK1827461T3 (da) 2004-12-22 2005-12-20 Cladribin-regimen til behandling af multipel sklerose

Country Status (11)

Country Link
AT (1) ATE547106T1 (da)
CY (1) CY1125491T1 (da)
DK (1) DK1827461T3 (da)
ES (4) ES2428741T3 (da)
HU (1) HUE035859T2 (da)
LT (1) LT2805723T (da)
ME (1) ME01333B (da)
PT (4) PT3332789T (da)
RS (1) RS52219B (da)
SI (1) SI1827461T1 (da)
UA (1) UA96260C2 (da)

Also Published As

Publication number Publication date
PT2805723T (pt) 2018-01-25
HUE035859T2 (en) 2018-05-28
CY1125491T1 (el) 2025-05-09
ME01333B (me) 2013-12-20
SI1827461T1 (sl) 2012-05-31
LT2805723T (lt) 2018-02-12
PT1827461E (pt) 2012-05-07
UA96260C2 (ru) 2011-10-25
PT3332789T (pt) 2022-07-05
PT4070800T (pt) 2024-12-30
ES2495392T3 (es) 2014-09-17
ES2666146T3 (es) 2018-05-03
RS52219B (sr) 2012-10-31
ES2382554T3 (es) 2012-06-11
ATE547106T1 (de) 2012-03-15
ES2428741T3 (es) 2013-11-11

Similar Documents

Publication Publication Date Title
TW200806300A (en) New therapeutic combinations for the treatment of depression
NO20073813L (no) Kladribinregime for behandling av multippel sklerose
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
WO2012007877A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
SG170069A1 (en) Quinoline derivatives
GEP20156348B (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
TW200833670A (en) Novel compounds 569
MX354173B (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas.
DE60219005D1 (de) Feste pharmazeutische formulierung enthaltend modafinil
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
BRPI0407181A (pt) Formulação farmacêutica
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
TW200745122A (en) New compounds I
SE0303480D0 (sv) Benzofuranes
WO2007111983A3 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007099323A3 (en) Quinoline derivatives
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
DK1827461T3 (da) Cladribin-regimen til behandling af multipel sklerose
TW200635592A (en) Pyridyl-substituted spiro-hydantoin compounds and use thereof
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
BRPI0618370A2 (pt) formulação aerossol de medicamento, uso do mesmo e kit de inalação